Exact Sciences Corporation (EXAS) Stock Forecast
Data as of Aug 2, 2026Healthcare · Current price $104.91 (+1.00%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
EXAS vs Sector & Market
| Metric | EXAS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.25 | 2.42 |
| Analyst Count | 20 | 8 | 19 |
| Target Upside | -11.4% | +16316.2% | +17.1% |
| P/E Ratio | — | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $3.53B | $3.69B | $3.80B | 9 |
| 2027-03-31 | $952M | $980M | $1.00B | 3 |
| 2027-06-30 | $1.02B | $1.06B | $1.08B | 2 |
| 2027-09-30 | $1.06B | $1.09B | $1.11B | 2 |
| 2027-12-31 | $1.08B | $1.11B | $1.14B | 3 |
| 2028-03-31 | $960M | $988M | $1.01B | 2 |
| 2028-06-30 | $1.05B | $1.08B | $1.11B | 1 |
| 2028-09-30 | $1.12B | $1.16B | $1.18B | 1 |
| 2028-12-31 | $1.14B | $1.17B | $1.20B | 2 |
| 2029-12-31 | $4.56B | $4.93B | $5.12B | 3 |
| 2030-12-31 | $4.75B | $5.12B | $5.32B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.15 | $0.18 | $0.21 | 4 |
| 2027-03-31 | $0.25 | $0.26 | $0.27 | 1 |
| 2027-06-30 | $0.45 | $0.47 | $0.48 | 1 |
| 2027-09-30 | $0.41 | $0.43 | $0.44 | 1 |
| 2027-12-31 | $0.38 | $0.39 | $0.40 | 1 |
| 2028-03-31 | $0.05 | $0.05 | $0.05 | 1 |
| 2028-06-30 | $0.47 | $0.49 | $0.50 | 1 |
| 2028-09-30 | $0.43 | $0.45 | $0.46 | 1 |
| 2028-12-31 | $0.54 | $0.56 | $0.58 | 1 |
| 2029-12-31 | $1.89 | $2.08 | $2.19 | 1 |
| 2030-12-31 | $2.83 | $3.13 | $3.29 | 1 |
Frequently Asked Questions
What is the analyst consensus for EXAS?
The consensus among 20 analysts covering Exact Sciences Corporation (EXAS) is Buy with an average price target of $105.00.
What is the highest price target for EXAS?
The highest analyst price target for EXAS is $105.00.
What is the lowest price target for EXAS?
The lowest analyst price target for EXAS is $105.00.
How many analysts cover EXAS?
20 analysts have issued ratings for Exact Sciences Corporation in the past 12 months.
Is EXAS a buy or sell right now?
Based on 20 analyst ratings, EXAS has a consensus rating of Buy (2.50/5) with a -11.4% upside to the consensus target of $105.00.
What are the earnings estimates for EXAS?
Analysts estimate EXAS will report EPS of $0.18 for the period ending 2026-12-31, with revenue estimated at $3.69B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.